Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Metastasis | Research article

Development and validation of nomograms for predicting axillary non-SLN metastases in breast cancer patients with 1–2 positive sentinel lymph node macro-metastases: a retrospective analysis of two independent cohorts

Authors: Yang Yu, Zhijun Wang, Zhongyin Wei, Bofan Yu, Peng Shen, Yuan Yan, Wei You

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

It is reported that appropriately 50% of early breast cancer patients with 1–2 positive sentinel lymph node (SLN) micro-metastases could not benefit from axillary lymph node dissection (ALND) or breast-conserving surgery with whole breast irradiation. However, whether patients with 1–2 positive SLN macro-metastases could benefit from ALND remains unknown. The aim of our study was to develop and validate nomograms for assessing axillary non-SLN metastases in patients with 1–2 positive SLN macro-metastases, using their pathological features alone or in combination with STMs.

Methods

We retrospectively reviewed pathological features and STMs of 1150 early breast cancer patients from two independent cohorts. Best subset regression was used for feature selection and signature building. The risk score of axillary non-SLN metastases was calculated for each patient as a linear combination of selected predictors that were weighted by their respective coefficients.

Results

The pathology-based nomogram possessed a strong discrimination ability for axillary non-SLN metastases, with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.727 (95% CI: 0.682–0.771) in the primary cohort and 0.722 (95% CI: 0.653–0.792) in the validation cohort. The addition of CA 15–3 and CEA can significantly improve the performance of pathology-based nomogram in the primary cohort (AUC: 0.773 (0.732–0.815) vs. 0.727 (0.682–0.771), P < 0.001) and validation cohort (AUC: (0.777 (0.713–0.840) vs. 0.722 (0.653–0.792), P < 0.001). Decision curve analysis demonstrated that the nomograms were clinically useful.

Conclusion

The nomograms based on pathological features can be used to identify axillary non-SLN metastases in breast cancer patients with 1–2 positive SLN. In addition, the combination of STMs and pathological features can identify patients with patients with axillary non-SLN metastases more accurately than pathological characteristics alone.

DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439–48. https://doi.org/10.3322/caac.21412.CrossRefPubMed

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–33. https://doi.org/10.1016/S1470-2045(10)70207-2.CrossRefPubMedPubMedCentral

Dingemans SA, de Rooij PD, van der Vuurst de Vries RM, Budel LM, Contant CM, van der Pool AE. Validation of six Nomograms for predicting non-sentinel lymph node metastases in a Dutch breast Cancer population. Ann Surg Oncol. 2016;23(2):477–81. https://doi.org/10.1245/s10434-015-4858-8.CrossRefPubMed

Mittendorf EA, Hunt KK, Boughey JC, Bassett R, Degnim AC, Harrell R, et al. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg. 2012;255(1):109–15. https://doi.org/10.1097/SLA.0b013e318238f461.CrossRefPubMedPubMedCentral

Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast Cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(5):561–4. https://doi.org/10.1200/JCO.2016.71.0947.CrossRefPubMed

Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98(9):599–609. https://doi.org/10.1093/jnci/djj158.CrossRefPubMed

Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10(10):1140–51. https://doi.org/10.1245/aso.2003.03.015.CrossRefPubMed

Degnim AC, Reynolds C, Pantvaidya G, Zakaria S, Hoskin T, Barnes S, et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg. 2005;190(4):543–50. https://doi.org/10.1016/j.amjsurg.2005.06.008.CrossRefPubMed

Klar M, Foeldi M, Markert S, Gitsch G, Stickeler E, Watermann D. Good prediction of the likelihood for sentinel lymph node metastasis by using the MSKCC nomogram in a German breast cancer population. Ann Surg Oncol. 2009;16(5):1136–42. https://doi.org/10.1245/s10434-009-0399-3.CrossRefPubMed

10.

van la Parra RF, Ernst MF, Bevilacqua JL, Mol SJ, Van Zee KJ, Broekman JM, et al. Validation of a nomogram to predict the risk of nonsentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy: validation of the MSKCC breast nomogram. Ann Surg Oncol. 2009;16(5):1128–35. https://doi.org/10.1245/s10434-009-0359-y.CrossRef

11.

Li X, Dai D, Chen B, He S, Zhang J, Wen C, et al. Prognostic Values Of Preoperative Serum CEA And CA125 Levels And Nomograms For Young Breast Cancer Patients. Onco Targets Ther. 2019;12:8789–800.CrossRef

12.

Nam SE, Lim W, Jeong J, Lee S, Choi J, Park H, et al. The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean breast Cancer society registry. Breast Cancer Res Treat. 2019;177(3):669–78. https://doi.org/10.1007/s10549-019-05357-y.CrossRefPubMed

13.

Coutant C, Olivier C, Lambaudie E, Fondrinier E, Marchal F, Guillemin F, et al. Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol. 2009;27(17):2800–8. https://doi.org/10.1200/JCO.2008.19.7418.CrossRefPubMed

14.

Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak. 2006;26(6):565–74. https://doi.org/10.1177/0272989X06295361.CrossRef

15.

Van Calster B, Wynants L, Verbeek JFM, Verbakel JY, Christodoulou E, Vickers AJ, et al. Reporting and interpreting decision curve analysis: a guide for investigators. Eur Urol. 2018;74(6):796–804. https://doi.org/10.1016/j.eururo.2018.08.038.CrossRefPubMedPubMedCentral

16.

Koca B, Kuru B, Ozen N, Yoruker S, Bek Y. A breast cancer nomogram for prediction of non-sentinel node metastasis - validation of fourteen existing models. Asian Pac J Cancer Prev. 2014;15(3):1481–8. https://doi.org/10.7314/APJCP.2014.15.3.1481.CrossRefPubMed

17.

Yildiz R, Urkan M, Hancerliogullari O, Kilbas Z, Ozturk E, Mentes MO, et al. Comparison of five different popular scoring systems to predict nonsentinel lymph node status in patients with metastatic sentinel lymph nodes: a tertiary care center experience. Springerplus. 2015;4:651.CrossRef

18.

Donker M, Straver ME, van Tienhoven G, van de Velde CJ, Mansel RE, Litiere S, et al. Comparison of the sentinel node procedure between patients with multifocal and unifocal breast cancer in the EORTC 10981-22023 AMAROS trial: identification rate and nodal outcome. Eur J Cancer. 2013;49(9):2093–100. https://doi.org/10.1016/j.ejca.2013.02.017.CrossRefPubMed

19.

Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they? Mol Oncol. 2010;4(3):192–208. https://doi.org/10.1016/j.molonc.2010.04.004.CrossRefPubMedPubMedCentral

20.

Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010;12(4):207. https://doi.org/10.1186/bcr2607.CrossRefPubMedPubMedCentral

21.

Kurebayashi J, Kanomata N, Shimo T, Yamashita T, Aogi K, Nishimura R, et al. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone. Breast Cancer. 2014;21(2):214–22. https://doi.org/10.1007/s12282-012-0380-z.CrossRefPubMed

22.

Hill AD, Tran KN, Akhurst T, Yeung H, Yeh SD, Rosen PP, et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg. 1999;229(4):528–35. https://doi.org/10.1097/00000658-199904000-00012.CrossRefPubMedPubMedCentral

23.

Gur AS, Unal B, Ozbek U, Ozmen V, Aydogan F, Gokgoz S, et al. Validation of breast cancer nomograms for predicting the non-sentinel lymph node metastases after a positive sentinel lymph node biopsy in a multi-center study. Eur J Surg Oncol. 2010;36(1):30–5. https://doi.org/10.1016/j.ejso.2009.05.007.CrossRefPubMed

24.

Chen JY, Chen JJ, Xue JY, Chen Y, Liu GY, Han QX, et al. Predicting non-sentinel lymph node metastasis in a Chinese breast Cancer population with 1-2 positive sentinel nodes: development and assessment of a new predictive Nomogram. World J Surg. 2015;39(12):2919–27. https://doi.org/10.1007/s00268-015-3189-z.CrossRefPubMed

25.

Abdessalam SF, Zervos EE, Prasad M, Farrar WB, Yee LD, Walker MJ, et al. Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am J Surg. 2001;182(4):316–20. https://doi.org/10.1016/S0002-9610(01)00719-X.CrossRefPubMed

26.

Bevilacqua JL, Kattan MW, Fey JV, Cody HS 3rd, Borgen PI, Van Zee KJ. Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol. 2007;25(24):3670–9. https://doi.org/10.1200/JCO.2006.08.8013.CrossRefPubMed

27.

Van Calster B, Vanden Bempt I, Drijkoningen M, Pochet N, Cheng J, Van Huffel S, et al. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. Breast Cancer Res Treat. 2009;113(1):181–7. https://doi.org/10.1007/s10549-008-9914-7.CrossRefPubMed

28.

Padmanabhan N, Ayub MF, Hussain K, Kurien A, Radhakrishna S. Factors influencing non-sentinel node involvement in sentinel node positive patients and validation of MSKCC Nomogram in Indian breast Cancer population. Indian J Surg Oncol. 2015;6(4):337–45. https://doi.org/10.1007/s13193-015-0431-y.CrossRefPubMedPubMedCentral

29.

Sanjuan A, Escaramis G, Vidal-Sicart S, Illa M, Zanon G, Pahisa J, et al. Predicting non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement: evaluation of two scoring systems. Breast J. 2010;16(2):134–40. https://doi.org/10.1111/j.1524-4741.2009.00892.x.CrossRefPubMed

30.

Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, et al. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 2008;8:66.CrossRef

31.

Wang W, Xu X, Tian B, Wang Y, Du L, Sun T, et al. The diagnostic value of serum tumor markers CEA, CA19–9, CA125, CA15–3, and TPS in metastatic breast cancer. Clin Chim Acta. 2017;470:51–5.CrossRef

Title: Development and validation of nomograms for predicting axillary non-SLN metastases in breast cancer patients with 1–2 positive sentinel lymph node macro-metastases: a retrospective analysis of two independent cohorts
Authors: Yang Yu
Zhijun Wang
Zhongyin Wei
Bofan Yu
Peng Shen
Yuan Yan
Wei You
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Metastasis
Cancer Biomarker
Breast Cancer
Breast Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08178-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach – a population-based study

Hā Ora: secondary care barriers and enablers to early diagnosis of lung cancer for Māori communities

18F-FDG-PET-MRI for the assessment of acute intestinal graft-versus-host-disease (GvHD)

Ablative radiation therapy to restrain everything safely treatable (ARREST): study protocol for a phase I trial treating polymetastatic cancer with stereotactic radiotherapy

Development and validation of multiparametric MRI-based nomogram for predicting occult metastasis risk in early tongue squamous cell carcinoma

Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer